Atrium Therapeutics, Inc.: quarterly results

RNANASDAQHealthcare · Pharmaceutical PreparationsNew listingsince Feb 26, 2026

Price

$6.92

November 20, 2026Market cap $149M

Results, quarter by quarter

When the company put out each quarter's results (its 8-K, item 2.02), what they showed against the same quarter a year before, and how the stock moved on the first session after.

Nov 12, 2026 last results

Next results

in 82 daysAround Feb 12, 2027 · for Q4 2026

last Nov 12, 2026next Feb 12, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

The first session after results

±1.5%average move, either way

2 times upof the last 31 times down

Largest: +4.1% on Aug 14, 2026 (Q2 2026).

How the stock moved after each release

The close of the first session after the results against the close before them.

RNA that sessionS&P 500 the same day

Every release

Revenue and diluted EPS of the quarter reported, with the change against the same quarter a year before.

  • Q3 2026
    Stock, next session+0.1%
  • Q2 2026
    Stock, next session+4.1%
  • Q1 2026
    Stock, next session-0.3%

Times are the SEC's acceptance of the 8-K, in New York time: before 16:00 the market traded on it that day, after it the next day. A move on a results day has other causes too, and says nothing about the next one.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.